Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


EDF Named UCL Enterprise Partner of the Year 2011

20 May 2011

EDF have been named UCL Enterprise Partner of the Year in recognition of their strong collaborative work with UCL.